Table of Contents May 06, 2024; Volume Issue Supplement 1
Kang, Fei
- You have accessRecent Advances in Radiotracers Targeting Novel Cancer-Specific Biomarkers in China: A Brief OverviewJingming Zhang, Fei Kang, Xiao Wang, Xuejiao Chen, Xing Yang, Zhi Yang and Jing WangJournal of Nuclear Medicine May 1, 2024, 65 (Supplement 1) 38S-45S; DOI: https://doi.org/10.2967/jnumed.123.266314
- You have accessLandscape of Nuclear Medicine in China and Its Progress on TheranosticsWeidong Yang, Fei Kang, Yue Chen, Zhaohui Zhu, Feng Wang, Chunxia Qin, Jin Du, Xiaoli Lan and Jing WangJournal of Nuclear Medicine May 1, 2024, 65 (Supplement 1) 29S-37S; DOI: https://doi.org/10.2967/jnumed.123.266968
- You have accessFibroblast Activation Protein Inhibitor Tracers and Their Preclinical, Translational, and Clinical Status in ChinaLiang Zhao, Fei Kang, Yizhen Pang, Jianyang Fang, Long Sun, Hua Wu, XiaoLi Lan, Jing Wang and Haojun ChenJournal of Nuclear Medicine May 1, 2024, 65 (Supplement 1) 4S-11S; DOI: https://doi.org/10.2967/jnumed.123.266983
- You have accessMelanin-Targeting Radiotracers and Their Preclinical, Translational, and Clinical Status: From Past to FutureXiao Zhang, Zhaoguo Lin, Yuan Feng, Fei Kang, Jing Wang and Xiaoli LanJournal of Nuclear Medicine May 1, 2024, 65 (Supplement 1) 19S-28S; DOI: https://doi.org/10.2967/jnumed.123.266945
Kong, Xiangxing
- You have accessThe Role of Total-Body PET in Drug Development and Evaluation: Status and OutlookXiangxi Meng, Xiangxing Kong, Lei Xia, Runze Wu, Hua Zhu and Zhi YangJournal of Nuclear Medicine May 1, 2024, 65 (Supplement 1) 46S-53S; DOI: https://doi.org/10.2967/jnumed.123.266978